Microbiome
Research News
Prescient Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening
Research will examine prevalent gut microbial markers present in colorectal cancer CARLSBAD, Calif., June 2, 2020 /PRNewswire/ -- Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., announced today a research...
Prescient Metabiomics and CoreBiome collaborating to develop breakthrough colon cancer screening test
CARLSBAD, Calif., Dec. 17, 2019 /PRNewswire/ -- Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., and CoreBiome, a wholly owned subsidiary of OraSure Technologies, Inc., announced today a collaboration to develop a new test called LifeKit®...
Abstract: Use of the Microbiome as a Biomarker to Identify Patients with Colorectal Polyps
A prospective study of patients undergoing screening or surveillance colonoscopy was performed to determine if a unique microbiome pattern could be used to identify patients with colorectal polyps (hyperplastic and adenoma).
Metabiomics Concludes Colorectal Polyp Study with 232 Subjects Enrolled
Metabiomics is proud to announce the completion of one of the largest case-controlled studies on the colorectal polyp microbiome.
Metabiomics Launches IRB approved Colon Polyp and Colon Cancer Diagnostics Clinical Research Study
Metabiomics launches a new IRB approved microbiome colon cancer diagnostics clinical research study titled “Metabiomics Neoplasia Clinical Research Study,” The study is also often referred to as MB-01.
MultiTag™ Sequencing Patent Award in US Clears Path for Metabiomics Colorectal Cancer and Gastrointestinal Disease Molecular Diagnostic Clinical Trials
The award today of US Patent 8,603,749, MutiTag Sequencing for Ecogenomics Analysis, represents a major milestone for Metabiomics by providing exclusive rights to fundamental next-generation DNA sequencing analysis technology for multiplexed ‘barcoded” sequencing of multiple samples in high-throughput analyses in the field of gastrointestinal diagnostics and therapeutic biomarker discovery.
Microbiome Biomarker and Diagnostic Patent Awarded by EPO
Metabiomics® announced today that it has been awarded patent number EP 1815016 B1 titled “Compositions and Methods for Diagnosing Colon Disorders” by the European Patent Office (EPO).
New Health Sciences Frontiers in Metagenomics and the Human Microbiome
It is not often that health sciences takes off in leaps and bounds on a whole new branch of discovery. Systems Biology scientists are exploring the Metagenome and Microbiome of Humans to map their interactive genetic and metabolic functions.We define the complex...
MultiTag Sequencing™ Services Now Available for Genomics Research Applications
Manassas, VA (April 15, 2009) -- Metabiomics© is now offering the human Genomics research community advanced MultiTag Sequencing™ primers and services including a limited license to use its patent pending MultiTag Sequencing™ method for research purposes. This...
Metabiomics Awarded Qualifying Therapeutic Discovery Project Grant
Biotechnology Grant Award Launches Metabiomics Human Microbiome Commercialization Initiative Potomac Falls, Virginia – November 5, 2010: Metabiomics, a human microbiome biomarker discovery and molecular diagnostics company, announced that that it was awarded a grant...